Oncology

Latest News

Doctor carrying documentation for patient care | image credit: Kanisorn - stock.adobe.com.jpeg
NCODA Outlines New Patient-Centered Oncology Distribution Models

May 1st 2025

Experts champion medically integrated care and oncology optimized distribution models as vital strategies to improve outcomes, streamline access, and reduce costs for patients.

The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com
New Developments Warrant Rethinking HCC Transplant Criteria

April 29th 2025

Women with fatigue | Image credit: Adobe Stock
Fatigue, Depression Hit Harder on Women Cancer Survivors, Data Show

April 29th 2025

senior scientist | Image credit: Ohio State University
Proving the Concept: A Sampler of Early-Stage Science at AACR 2025

April 28th 2025

NSCLC | Image: Lung Cancer Foundation of America
Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

April 28th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
March 3rd 2020

Managed Care Considerations for Navigating Biosimilar and HER2-Directed Therapies for the Treatment of HER2-Positive Breast Cancer

https://www.pharmacytimes.org/on-demand/managed-care-considerations-for-navigating-biosimilar-and-her2-directed-therapies-for-the-treatment-of-her2-positive-breast-cancer
Site Logo
March 3rd 2020

Innovation and Novel Therapies

Laura Joszt, MA Mary Caffrey
During a discussion at The American Journal of Managed Care®’s Patient- Centered Oncology Care® meeting in Philadelphia, panelists outlined the efficacy of the 2 FDA-approved therapies, Medicare reimbursement for CAR T-cell therapies, and the pace of innovation in healthcare.
PAPER OF THE WEEK: Predictions About Clinical Pathways
February 22nd 2020

PAPER OF THE WEEK: Predictions About Clinical Pathways

Mary Caffrey
With our current issue of Evidence-Based Oncology™ focusing on clinical pathways in cancer care, we look back at one of our most-read papers of 2016.
Site Logo
February 21st 2020

Overall US Cancer Mortality Rate Reaches 26-Year Decline, but Obesity-Related Cancer Deaths Rise

Matthew Gavidia
The decline can be attributed to long-term drops in death rates for the 4 major cancers—lung, colorectal, breast, and prostate.
Site Logo
February 19th 2020

From the Editor-in-Chief: The End of the Beginning

Joseph Alvarnas, MD
Dr Alvarnas is editor-in-chief of Evidence-Based Oncology.™ He is vice president of Government Affairs, senior medical director for Employer Strategy, and associate clinical professor, Hematology & Hematologic Cell Transplantation, City of Hope, Duarte, Califonia.
Site Logo
February 19th 2020

Lessons From the Front: Designing and Implementing Clinical Pathways by and for Clinicians

David M. Jackman, MD Joanna Hamilton, MA, MS Emily Foster, MPH Craig A. Bunnell, MD, MPH, MBA Louis Culot, MA Carole Tremonti, RN, MBA Joseph O. Jacobson, MD, MSc
As cancer care becomes more complex and more expensive, decision-support algorithms offer a mechanism to define best practice, reduce unwarranted variation, and control costs across growing networks.
This Week in Managed Care: February 7, 2020
February 8th 2020

This Week in Managed Care: February 7, 2020

This week, top managed care stories included survey results on oncology practices’ willingness to take on risk; a warning of flu among children in detention centers; study findings establishing a link between circadian rhythm and type 2 diabetes.
Dr Joshua Ofman: Improving Survival, Reducing Costs in Oncology Vital to Value-Based Care Transition
February 6th 2020

Dr Joshua Ofman: Improving Survival, Reducing Costs in Oncology Vital to Value-Based Care Transition

From a value-based medicine perspective, we think there's no greater value in the healthcare system than improving survival for cancer patients and reducing the costs of treating late stage cancer; we believe the GRAIL test could be the test case for how to make this transition, said Joshua Ofman, MD, MSHS, chief of Corporate Strategy and External Affairs at GRAIL Inc.
Site Logo
February 5th 2020

A Population-Based Assessment of Proton Beam Therapy Utilization in California

Arti Parikh-Patel, PhD, MPH Cyllene R. Morris, DVM, PhD Frances B. Maguire, PhD, MPH Megan E. Daly, MD Kenneth W. Kizer, MD, MPH
This population-based analysis of patients with cancer in California found significant differences in proton beam therapy use by health insurance type, race/ethnicity, and socioeconomic status.
Site Logo
January 28th 2020

American Oncology Network, LLC, Names Todd Schonherz President and Chief Operating Officer

Schonherz will be responsible for day-to-day operations.
CMS Agrees to Cover NGS for Medicare Patients With Breast, Ovarian, Other Cancers
January 28th 2020

CMS Agrees to Cover NGS for Medicare Patients With Breast, Ovarian, Other Cancers

Allison Inserro Mary Caffrey
CMS said it is expanding coverage of next generation sequencing (NGS) for use as a diagnostic for patients with germline breast and ovarian cancer, paving the way for Medicare beneficiaries to receive more personalized medicine. However, an advocate said the wording of CMS' decision could actually limit testing access for some women with breast or ovarian cancer.
Site Logo
January 21st 2020

Bundled Payments: Looking Back, Looking Ahead

Alyssa Dahl, MPH
Jennifer Atkins Explains How Blue Cross Blue Shield Evaluates Emerging Innovations in Cancer Care
January 17th 2020

Jennifer Atkins Explains How Blue Cross Blue Shield Evaluates Emerging Innovations in Cancer Care

Blue Cross Blue Shield utilizes data to drive insights into what works and what doesn't work in cancer care, as well as, delineating trends through our collaboration with provider specialties and organizations across the US, said Jennifer Atkins, MBA, vice president of Network Solutions at Blue Cross Blue Shield.
When Less Is More: Halving Chemo Keeps Testicular Cancer at Bay, Study Finds
January 4th 2020

When Less Is More: Halving Chemo Keeps Testicular Cancer at Bay, Study Finds

Mary Caffrey
Testicular cancer is the most common cancer to be diagnosed in men as younger men—those younger than age 40—and it can be particularly aggressive. Advances in therapy have improved survival rates, but if young men have chemotherapy after surgery, they may live with side effects for decades.
What We're Reading: Healthcare Issues to Watch; e-Cig Flavor Ban; Google AI and Breast Cancer
January 2nd 2020

What We're Reading: Healthcare Issues to Watch; e-Cig Flavor Ban; Google AI and Breast Cancer

AJMC Staff
Five issues in healthcare were spotlighted as key developments to watch; FDA to ban all e-cig vape flavors except for menthol and tobacco; Google AI system shown to improve detection of breast cancer through mammograms.
An Immune-Suppressing Target for Glioblastoma?
December 27th 2019

An Immune-Suppressing Target for Glioblastoma?

Mary Caffrey
A team at The University of Texas MD Anderson Cancer Center in Houston led by original pioneers in immuno-oncology have published a paper in Nature Medicine that discusses an immune-suppressing enzyme that was strongly present in glioblastoma but not in 5 other tumor types the team studied.
Site Logo
December 19th 2019

Improving Survival in Lung Cancer: Commitment of The Lung Ambition Alliance

Giorgio Scagliotti, MD, PhD
For more than 45 years, the International Association for the Study of Lung Cancer has been working tirelessly toward a world without lung and other thoracic cancers. To add strength to our efforts we recently joined with other leading organizations in the lung cancer space to create a powerful force for change: The Lung Ambition Alliance
Future of BCC and CSCC Therapy
December 19th 2019

Future of BCC and CSCC Therapy

Second-Line Systemic Treatment of BCC
December 19th 2019

Second-Line Systemic Treatment of BCC

Systemic Therapy in BCC
December 19th 2019

Systemic Therapy in BCC

Electing for Surgery in the Management of BCC
December 19th 2019

Electing for Surgery in the Management of BCC

Overview of Basal Cell Carcinoma
December 19th 2019

Overview of Basal Cell Carcinoma

Toxicity Profile and Pseudoprogression
December 19th 2019

Toxicity Profile and Pseudoprogression

PD-1 and Other Systemic Treatment Options for CSCC
December 19th 2019

PD-1 and Other Systemic Treatment Options for CSCC

Using Immunotherapy in CSCC
December 19th 2019

Using Immunotherapy in CSCC

Systemic Treatment of CSCC
December 19th 2019

Systemic Treatment of CSCC

Standard of Care for CSCC
December 19th 2019

Standard of Care for CSCC

Overview of Cutaneous Squamous Cell Carcinoma
December 19th 2019

Overview of Cutaneous Squamous Cell Carcinoma

Site Logo
December 18th 2019

Radiation Oncologist Discusses Concerns With Incoming CMS Payment Model

Allison Inserro
As CMS prepares to move forward with new models of value-based cancer care, a radiation oncologist, speaking at the Institute for Value-Based Medicine®, discussed her findings regarding whether accountable care models had an effect on cancer care spending.
Site Logo
December 18th 2019

Hope and Some Skepticism Whether Oncology Payment Models Will Work

Allison Inserro
Coverage from the Institute for Value-Based Medicine® session held in Nashville, Tennessee.
<1
...
181920212223242526
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo